1Tzschentke, TM. Glutamatergic mechanisms in different disease states: overview and therapeutical implications – an introduction. Amino Acids 2002;23:147–152.
2Kalia, LV, Kalia, SK, Salter, MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 2008;7:742–755.
3Sukhanov, IM, Zakharova, ES, Danysz, W, Bespalov, AY. Effects of NMDA receptor channel blockers, MK‐801 and memantine, on locomotor activity and tolerance to delay of reward in Wistar‐Kyoto and spontaneously hypertensive rats. Behav Pharmacol 2004;15:263–271.
4Mares, P, Mikulecka, A. Different effects of two N‐methyl‐D‐aspartate receptor antagonists on seizures, spontaneous behavior, and motor performance in immature rats. Epilepsy Behav 2009;14:32–39.
5Andreassen, OA, Aamo, TO, Joorgensen, HA. Inhibition by memantine of the development of persistent oral dyskinesias induced by long‐term haloperidol treatment of rats. Br J Pharmacol 1996;119:751–757.
6Andreassen, OA, Waage, J, Finsen, B, Jorgensen, HA. Memantine attenuates the increase in striatal preproenkephalin mRNA expression and development of haloperidol‐induced persistent oral dyskinesias in rats. Brain Res 2003;994:188–192.
7Schwenkreis, P, Witscher, K, Pleger, B, Malin, JP, Tegenthoff, M. The NMDA antagonist memantine affects training induced motor cortex plasticity–a study using transcranial magnetic stimulation. BMC Neurosci 2005;6:35.
8Rammsayer, TH. NMDA receptor activity and the transmission of sensory input into motor output in introverts and extraverts. Q J Exp Psychol B 2003;56:207–221.
9Morrens, M, Hulstijn, W, Sabbe, B. Psychomotor slowing in schizophrenia. Schizophr Bull 2007;33:1038–1053.
10Pappa, S, Dazzan, P. Spontaneous movement disorders in antipsychotic‐naive patients with first‐episode psychoses: a systematic review. Psychol Med 2009;39:1065–1076.
11Berle, JO, Hauge, ER, Oedegaard, KJ, Holsten, F, Fasmer, OB. Actigraphic registration of motor activity reveals a more structured behavioural pattern in schizophrenia than in major depression. BMC Res Notes 2010;3:149.
12Di Mascio, M, Di Giovanni, G, Di Matteo, V, Esposito, E. Decreased chaos of midbrain dopaminergic neurons after serotonin denervation. Neuroscience 1999;92:237–243.
13Ehlers, CL. Chaos and complexity. Can it help us to understand mood and behavior? Arch Gen Psychiatry 1995;52:960–964.
14Huikuri, HV, Makikallio, TH, Peng, CK, Goldberger, AL, Hintze, U, Moller, M. Fractal correlation properties of R‐R interval dynamics and mortality in patients with depressed left ventricular function after an acute myocardial infarction. Circulation 2000;101:47–53.
15Ilias, I, Vgontzas, AN, Provata, A, Mastorakos, G. Complexity and non‐linear description of diurnal cortisol and growth hormone secretory patterns before and after sleep deprivation. Endocr Regul 2002;36:63–72.
16Kramlinger, KG, Post, RM. Ultra‐rapid and ultradian cycling in bipolar affective illness. Br J Psychiatry 1996;168:314–323.
17Liu, PY, Iranmanesh, A, Keenan, DM, Pincus, SM, Veldhuis, JD. A noninvasive measure of negative‐feedback strength, approximate entropy, unmasks strong diurnal variations in the regularity of LH secretion. Am J Physiol Endocrinol Metab 2007;293:E1409–E1415.
18Tuzcu, V, Nas, S, Borklu, T, Ugur, A. Decrease in the heart rate complexity prior to the onset of atrial fibrillation. Europace 2006;8:398–402.
19Aboy, M, Cuesta‐Frau, D, Austin, D, Mico‐Tormos, P. Characterization of sample entropy in the context of biomedical signal analysis. Conf Proc IEEE Eng Med Biol Soc 2007;2007:5943–5946.
20Hauge, ER, Berle, JO, Oedegaard, KJ, Holsten, F, Fasmer, OB. Nonlinear analysis of motor activity shows differences between schizophrenia and depression: a study using Fourier analysis and sample entropy. PLoS One 2011;6:e16291.
21Rhoades, HM, Overall, JE. The semistructured BPRS interview and rating guide. Psychopharmacol Bull 1988;24:101–104.
22Nose, M, Tansella, M, Thornicroft, G, et al. Is the Defined Daily Dose system a reliable tool for standardizing antipsychotic dosages? Int Clin Psychopharmacol 2008;23:287–290.
23Parsons, CG, Danysz, W, Quack, G. Memantine is a clinically well tolerated N‐methyl‐D‐aspartate (NMDA) receptor antagonist–a review of preclinical data. Neuropharmacology 1999;38:735–767.
24Richman, JS, Moorman, JR. Physiological time‐series analysis using approximate entropy and sample entropy. Am J Physiol Heart Circ Physiol 2000;278:H2039–H2049.
25Goldberger, AL, Amaral, LA, Glass, L, et al. PhysioBank, PhysioToolkit, and PhysioNet: components of a new research resource for complex physiologic signals. Circulation 2000;101:E215–E220.
26Fink, M, Shorter, E, Taylor, MA. Catatonia is not schizophrenia: Kraepelin's error and the need to recognize catatonia as an independent syndrome in medical nomenclature. Schizophr Bull 2010;36:314–320.
27Tandon, R, Jibson, MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry 2002;14:123–129.
28Howes, OD, Kapur, S. The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr Bull 2009;35:549–562.
29Korchounov, A, Meyer, MF, Krasnianski, M. Postsynaptic nigrostriatal dopamine receptors and their role in movement regulation. J Neural Transm 2010;117:1359–1369.
30Abi‐Dargham, A, Laruelle, M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005;20:15–27.
31Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second‐generation versus first‐generation antipsychotic drugs for schizophrenia: a meta‐analysis. Lancet 2009;373:31–41.
32Walther, S, Horn, H, Razavi, N, Koschorke, P, Muller, TJ, Strik, W. Quantitative motor activity differentiates schizophrenia subtypes. Neuropsychobiology 2009;60:80–86.